Journal of Clinical Oncology
Articles in this Issue
Endocrine adverse events associated with immunotherapy: A retrospective cohort study.
e23387 Background: Immunotherapy (IT) are a cornerstone of cancer therapy but are associated with immune-related adverse e...
mTOR activation and racial disparity in early breast cancer survival.
569 Background: Black women have lower survival rates following a diagnosis of estrogen receptor-positive (ER+) early brea...
Evaluation of butyrate and chenodeoxycholic acid (CDCA) for anti-inflammatory and hepatoprotective effects in various liver cancer models.
e16257 Background: The gut-liver relationship plays an important role in maintaining the intestinal barrier, regulating im...
Impact of HSPA6 on lenvatinib resistance in HCC via phase separation–mediated TXNRD1 stabilization and ferroptosis suppression.
4119 Background: Lenvatinib is a first-line treatment for advanced hepatocellular carcinoma (HCC), but its efficacy is fre...
Anti-tumor activity and safety of SYN429, a synthetic type I IFN.
e14561 Background: Immune checkpoint inhibitors (ICIs) are effective for some types of cancer; however, a large population...
Molecular profiling and perioperative management of inflammatory myofibroblastic tumors at a single institution.
e23519 Background: Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm often driven by kinase fusions, most common...
Immune-mediated toxicities (irAEs) in immune checkpoint inhibitor (ICI) therapy in various combinations: A real-world sample.
e23376 Background: ICI either alone or in combination with other ICI, tyrosine kinase Inhibitors (TKI), or chemotherapy (C...
AI-derived tumor microenvironment features and recurrence risk in microsatellite-stable colon cancer after adjuvant chemotherapy.
3646 Background: Despite adjuvant chemotherapy, a substantial number of patients with stage II–III microsatellite stable (...
HIV lymphomas in the safety-net setting: A decade of experience at a single institution.
e19113 Background: Safety-net hospitals treat disproportionately more HIV patients than other hospitals. HIV patients are...
Racial disparities in risk of second primary malignancies in esophageal cancer survivors: Insights from a population-based database.
e16090 Background: Racial disparities shape outcomes in esophageal cancer, yet their role in second primary malignancies (...
Investigator-initiated phase II trial of ABSK043, an oral PD-L1 inhibitor, in patients with angiogenic sarcoma.
TPS11593 Background: Angiogenic sarcomas (AS) represent a group of rare mesenchymal malignancies arising from the vascular...
Becotatug vedotin plus pucotenlimab as first-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial.
TPS6130 Background: Epidermal growth factor receptor (EGFR) is highly expressed in approximately 85% of nasopharyngeal car...
Follow-up of outpatients taking oral anticancer drugs in the multidisciplinary community hospital ONCORAL care plan.
1507 Background: The increasing use of oral anticancer drugs (OADs) has shifted cancer care toward outpatient and home-bas...
Final analysis of the TiNivo-2 phase 3 trial: Long-term outcome of tivozanib (Tivo) in patients with metastatic renal cell carcinoma (mRCC).
4555 Background: TiNivo-2 results showed that immune checkpoint inhibitor (ICI) rechallenge did not offer benefit to patie...
Evaluation of whole-exome and whole-genome sequencing tumor-informed circulating tumor DNA MRD assays in patients with early triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) with or without olaparib: A prospective sub-study of the PARTNER trial.
570 Background: Detection of molecular residual disease (MRD), using circulating tumor DNA (ctDNA), following treatment fo...
Incidence of anal cancer in the United States: An analysis of NPCR data and comparison to SEER, 1998-2017.
e15505 Background: Anal cancer is a rare malignancy with rising incidence in the United States. Most national epidemiologi...
Statistical data and mortality rates for prostate cancer from 1999 to 2021 in the population of United States-Mexico border areas: Insights from CDC WONDER.
e17106 Background: Prostate cancer is a leading cause of cancer-related mortality among U.S. men. Thisstudy analyzes prost...
Real-world outcomes of breast cancer central nervous system metastases treated with sacituzumab govitecan.
e13095 Background: Prior studies indicate that therapeutic concentrations of sacituzumab govitecan (SG) penetrate the cent...
A response-adapted and genomically informed strategy to optimize neoadjuvant chemotherapy versus endocrine therapy plus CDK4/6 inhibition in high-risk HR+/HER2− breast cancer.
591 Background: Premenopausal patients with locally advanced hormone receptor–positive, HER2-negative (HR+/HER2−) breast c...
Genomic determinants of resistance to BRAF/MEK inhibitors in <i>BRAF</i> <sup>V600E</sup> –mutant non–small cell lung cancer.
8647 Background: BRAF V600E mutations occur in approximately 2–3% of non–small cell lung cancer (NSCLC...
Safety and efficacy of daraxonrasib monotherapy as later-line (3L+) treatment for patients (pts) with metastatic pancreatic adenocarcinoma (PDAC).
e15104 Background: Later-line (3L+) treatment for PDAC remains a high unmet need, with historically poor outcomes with che...
Patient characteristics, treatment patterns, and survival in a metastatic pancreatic adenocarcinoma US patient population.
e16379 Background: Pancreatic adenocarcinoma (PDAC) is a leading cause of cancer-related deaths in the US. Clinical guidel...
Efficacy and safety of intra-arterial liver–directed therapies in unresectable neuroendocrine carcinoma liver metastases.
e16308 Background: Neuroendocrine carcinoma (NEC) is an aggressive malignancy characterized by rapid progression and high...
A first-in-human phase 1 dose-escalation study of the oral HIF-2α inhibitor JMKX003948 in patients with renal cell carcinoma.
4544 Background: Hypoxia inducible factor-2 alpha (HIF-2α) is a transcription factor and key tumorigenic driver of clear c...
Primary prevention of acute leukemias in high-risk patients: The therapeutic promise of GLP-1 receptor agonists.
10507 Background: Despite advances in understanding leukemogenesis, no validated primary prevention strategies exist. Obes...